Kyverna Therapeutics

Performance

About Kyverna Therapeutics

Kyverna Therapeutics is a clinical-stage biopharmaceutical company focused on developing cell therapies to treat autoimmune diseases. Its lead CAR T-cell therapy candidate mivocabtagene (miv-cel, KYV-101) is advancing through multiple phase trials in rheumatology and neurology, including lupus nephritis, stiff person syndrome, multiple sclerosis, myasthenia gravis, and systemic sclerosis, with trials conducted in the United States and Europe. The company pursues autologous and allogeneic CAR T-cell platforms aimed at deep B cell depletion and long-term immune reset for patients with autoimmune conditions. Kyverna emphasizes patient-centric clinical development and global collaboration to bring transformative cell therapies to patients living with autoimmune diseases.